Amgen To Acquire Privately-Held Dezima Pharma
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- S&P 500, Nasdaq slip as Iran tensions test markets in high-stakes week
- Oil falls ahead of US announcement of new sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- S&P 500, Nasdaq slip as Iran tensions test markets in high-stakes week
- RUM Group signs $13.7 billion GPU services deal, issues warrants
- XPeng Inc. (XPEV) Misses Q2 EPS by 100c ; Provides Outlook
- Funds sell $44bn in semiconductors on AI concerns
Leerink Partners Remains Bullish on Xencor, Inc. (XNCR) Following Announced Amgen Inc. (AMGN) Collaboration
September 16, 2015 10:10 AM EDTLeerink Partners reiterated an Outperform rating and $25.00 price target on Xencor, Inc. (NASDAQ: XNCR) following an announced collaboration with Amgen Inc. (NASDAQ: AMGN). The collaboration will combine AMGN's proprietary antibodies and XNCR's bispecific platform to develop new therapeutic candidates for cancer... More
Amgen (AMGN) to Acquire Dezima Pharma in $1.55B Deal
September 16, 2015 9:05 AM EDTAmgen (NASDAQ: AMGN) and Dezima Pharma B.V. (Dezima) today announced that the companies have entered into a definitive acquisition agreement under which Amgen will acquire Dezima, a privately-held, Netherlands-based biotechnology company focused on developing innovative treatments for dyslipidemia. Dezima shareholders have approved the agreement.
"With the recent launches of Repatha (evolocumab) and Corlanor® (ivabradine), and today's acquisition of Dezima, Amgen is proud to be on the leading edge of an exciting new wave of treatments for cardiovascular disease, an illness impacting millions of people worldwide," said Robert A. Bradway, chairman and chief... More
